WhaleCreep

RA Capital Management, L.P. 13F holdings, Q3 2022

Hedge fundSEC filingsCompare with another fundHoldings as of 2022-09-30, filed 2022-11-14

RA Capital Management, L.P. disclosed 81 US equity positions worth $4.7bn in its Q3 2022 13F filing. Its largest position is ASND at 16.7% of the reported book, followed by BIIB and CTKB. Versus Q2 2022 it opened 13 new positions, added to 10, reduced 7 and exited 20.

$4.7bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
81
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
16.7%
Largest position
The largest single position as a share of the reported equity book.
46.5%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
22
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
73
Quarters on file since Q4 2007
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q2 2022: 13 new, 10 added, 7 reduced, 20 exited

50 of 81
ASND ASCENDIS PHARMA A/SHealthcare16.7%$781m7.57m0.0%held
BIIB BIOGEN INCHealthcare5.3%$250m937,549+29%added
CTKB CYTEK BIOSCIENCES INCHealthcare4.2%$197m13.38m0.0%held
FORMA THERAPEUTICS HLDGS INC no ticker–3.8%$180m9.01m0.0%held
DAWNGBX DAY ONE BIOPHARMACEUTICALS I–3.0%$141m7.04m0.0%held
AEROVATE THERAPEUTICS INC no ticker–2.9%$137m8.26m0.0%held
RYTM RHYTHM PHARMACEUTICALS INCHealthcare2.9%$134m5.47m+12%added
TVTX TRAVERE THERAPEUTICS INCHealthcare2.6%$121m4.92m0.0%held
BLU BELLUS HEALTH INC NEW–2.6%$120m11.39m+11%added
JANX JANUX THERAPEUTICS INCHealthcare2.5%$117m8.67m0.0%held
PCVX VAXCYTE INCHealthcare2.3%$110m4.58m0.0%held
DICE THERAPEUTICS INC no ticker–2.3%$106m5.21m0.0%held
IMGNEUR IMMUNOGEN INC–2.2%$104m21.74m0.0%held
NKTX NKARTA INCHealthcare2.2%$103m7.81m0.0%held
ABOS ACUMEN PHARMACEUTICALS INCHealthcare2.1%$98.0m9.77m0.0%held
LEGN LEGEND BIOTECH CORPHealthcare2.0%$95.4m2.34m–new
2662247D ITEOS THERAPEUTICS INC–1.8%$84.1m4.42m0.0%held
RLMD RELMADA THERAPEUTICS INCHealthcare1.6%$74.0m2.00m0.0%held
PEPG PEPGEN INCHealthcare1.6%$73.8m8.13m0.0%held
GERN GERON CORPHealthcare1.5%$70.5m30.13m0.0%held
ACRS ACLARIS THERAPEUTICS INCHealthcare1.5%$69.2m4.40m0.0%held
THIRD HARMONIC BIO INC no ticker–1.4%$65.9m3.48m–new
ANTX AN2 THERAPEUTICS INCHealthcare1.4%$65.6m3.77m+0.7%added
TYRA TYRA BIOSCIENCES INCHealthcare1.4%$63.6m7.24m0.0%held
WVE WAVE LIFE SCIENCES LTDHealthcare1.3%$62.1m17.20m0.0%held
VRNA VERONA PHARMA PLC–1.3%$61.8m6.05m+19%added
COGT COGENT BIOSCIENCES INCHealthcare1.3%$59.9m4.01m–new
NSTGEUR NANOSTRING TECHNOLOGIES INC–1.3%$58.8m4.60m+28%added
CLDX CELLDEX THERAPEUTICS INC NEWHealthcare1.2%$58.3m2.08m0.0%held
GHRS GH RESEARCH PLCHealthcare1.2%$56.9m4.90m0.0%held
FULC FULCRUM THERAPEUTICS INCHealthcare1.2%$56.6m7.00m–new
KNTEUSD KINNATE BIOPHARMA INC–1.1%$51.0m4.26m0.0%held
ENTA ENANTA PHARMACEUTICALS INCHealthcare1.0%$46.5m896,7240.0%held
DSGN DESIGN THERAPEUTICS INCHealthcare1.0%$46.4m2.77m+27%added
ETNBGBP 89BIO INC–1.0%$45.1m7.78m0.0%held
VOR VOR BIOPHARMA INCHealthcare0.9%$44.3m11.12m0.0%held
CLYM CLIMB BIO INCHealthcare0.9%$42.5m13.15m0.0%held
TIL INSTIL BIO INCHealthcare0.8%$37.1m7.67m0.0%held
RXST RXSIGHT INCHealthcare0.8%$36.6m3.05m0.0%held
STSAUSD SATSUMA PHARMACEUTICALS INC–0.8%$35.5m5.91m0.0%held
RNAGBP AVIDITY BIOSCIENCES INC–0.8%$35.4m2.17m0.0%held
VERA VERA THERAPEUTICS INCHealthcare0.7%$33.6m1.58m0.0%held
RCKT ROCKET PHARMACEUTICALS INCHealthcare0.7%$33.6m2.11m0.0%held
AKROEUR AKERO THERAPEUTICS INC–0.7%$32.7m958,980–new
NVLSEUR ALPINE IMMUNE SCIENCES INC–0.7%$31.4m4.36m–new
HLVX HILLEVAX INC–0.6%$30.1m1.76m0.0%held
ACET ADICET BIO INCHealthcare0.6%$29.3m2.06m–new
EYPT EYEPOINT INCHealthcare0.6%$26.7m3.37m0.0%held
MIST MILESTONE PHARMACEUTICALS IN–0.4%$20.6m2.25m0.0%held
PMVP PMV PHARMACEUTICALS INCHealthcare0.4%$20.4m1.71m0.0%held

Exited since Q2 2022

20 rows
VERU VERU INC2.4%$89.3m
POINT BIOPHARMA GLOBAL INC no ticker1.6%$61.3m
NTRA NATERA INC1.2%$46.4m
DYN DYNE THERAPEUTICS INC0.5%$19.3m
GH GUARDANT HEALTH INC0.5%$19.2m
OTICEUR OTONOMY INC0.3%$11.6m
LIANY LIANBIO0.3%$10.0m
IPSC CENTURY THERAPEUTICS INC0.2%$6.4m
BMEA BIOMEA FUSION INC0.2%$6.0m
XLO XILIO THERAPEUTICS INC0.1%$4.8m
LAB STANDARD BIOTOOLS INC0.08%$3.2m
430 TERNS PHARMACEUTICALS INC0.08%$3.1m
BCAB BIOATLA INC0.08%$2.9m
CATBUSD ASTRIA THERAPEUTICS INC0.06%$2.3m
ADVMCHF ADVERUM BIOTECHNOLOGIES INC0.06%$2.1m
LRMR LARIMAR THERAPEUTICS INC0.05%$2.0m
ORTXUSD ORCHARD THERAPEUTICS PLC0.05%$1.8m
OLMA OLEMA PHARMACEUTICALS INC0.03%$952k
AVROBIO INC no ticker0.01%$515k
NBSEUR CALADRIUS BIOSCIENCES INC0.01%$399k

Sector mix

  • Healthcare68.3%
  • Unclassified31.7%

Book over time

Every quarter on file (73)
QuarterPositionsEquity book
Q2 202684$11.5bn
Q1 202685$9.4bn
Q4 202571$9.8bn
Q3 202567$8.1bn
Q2 202563$5.9bn
Q1 202585$6.0bn
Q4 202489$7.5bn
Q3 202481$8.7bn
Q2 202478$7.6bn
Q1 202476$7.9bn
Q4 202362$6.4bn
Q3 202366$5.1bn
Q2 202354$5.3bn
Q1 202359$4.4bn
Q4 202270$4.9bn
Q3 202281$4.7bn
Q2 202288$3.8bn
Q1 202296$4.6bn
Q4 202197$5.7bn
Q3 202195$7.2bn
Q2 202192$6.2bn
Q1 202182$6.6bn
Q4 202082$7.2bn
Q3 202070$5.5bn
Q2 202057$5.1bn
Q1 202048$3.2bn
Q4 201934$3.3bn
Q3 201932$1.7bn
Q2 201925$1.9bn
Q1 201929$2.3bn
Q4 201825$1.7bn
Q3 201826$1.9bn
Q2 201827$1.5bn
Q1 201831$1.3bn
Q4 201727$1.2bn
Q3 201727$1.1bn
Q2 201722$871m
Q1 201724$815m
Q4 201627$706m
Q3 201630$969m
Q2 201632$722m
Q1 201642$782m
Q4 201537$1.0bn
Q3 201547$696m
Q2 201558$928m
Q1 201556$913m
Q4 201448$777m
Q3 201443$622m
Q2 201424$756m
Q1 201429$973m
Q4 201324$648m
Q3 201331$724m
Q2 201325$616m
Q1 201317$407m
Q4 201219$225m
Q3 201221$198m
Q2 201226$223m
Q1 201223$185m
Q4 201118$124m
Q3 201120$90.3m
Q2 201120$108m
Q1 201121$130m
Q4 201016$101m
Q3 201018$101m
Q1 201021$102m
Q4 200914$75.1m
Q2 200916$107m
Q1 200912$184m
Q4 20088$224m
Q3 200820$329m
Q2 200822$220m
Q1 200817$135m
Q4 200723$159m

Where RA Capital Management, L.P. was early

110 rows
VRTX VERTEX PHARMACEUTICALS INCQ1 20082 of 16012.5%12.5%7Exited by Q4 2014+370%
AMAG AMAG PHARMACEUTICALS INCQ2 20081 of 693.4%9.2%7Exited by Q3 2010+2.4%
GILD GILEAD SCIENCES INCQ4 20087 of 1810.7%15.8%6Exited by Q2 2020+192%
BSTC BIOSPECIFICS TECHNOLOGIES COQ1 20091 of 299.0%32.9%7Exited by Q3 2011–
ALXN ALEXION PHARMACEUTICALS INCQ2 20092 of 1476.6%9.6%5Exited by Q2 2011–
UTHR UNITED THERAPEUTICS CORP DELQ2 20092 of 1617.0%7.0%5Exited by Q2 2011+61%
ENZB ENZO BIOCHEM INCQ1 20101 of 400.6%3.9%7Exited by Q1 2014–
ACAD ACADIA PHARMACEUTICALS INCQ1 20111 of 1456.5%21.1%17Exited by Q3 2015+2485%
NVAX NOVAVAX INCQ4 20111 of 1171.0%14.4%24Exited by Q2 2022+192%
SGMOQ SANGAMO THERAPEUTICS INCQ4 20111 of 852.0%13.6%22Exited by Q4 2017+428%
BCRX BIOCRYST PHARMACEUTICALS INCQ1 20121 of 1218.0%11.1%28Held at last filing, Q2 2026+107%
VSTM VERASTEM INCQ1 20121 of 1003.6%3.6%6Exited by Q4 2020−89%
IMMU IMMUNOMEDICS INCQ1 201311 of 1110.6%4.8%6Exited by Q1 2019+492%
ENTA ENANTA PHARMACEUTICALS INCQ2 20131 of 921.3%8.8%8Exited by Q1 2025−68%
INSM INSMED INCQ2 20131 of 1804.7%6.4%9Exited by Q2 2025+538%
OMER OMEROS CORPQ2 20131 of 662.4%2.4%4Exited by Q3 2015+257%
PRTA PROTHENA CORP PLCQ2 20131 of 1011.0%6.7%4Exited by Q2 2014+197%
TXMD THERAPEUTICSMD INCQ2 20131 of 655.5%9.4%13Exited by Q3 2021−61%
PTCT PTC THERAPEUTICS INCQ3 20131 of 1270.9%2.6%7Exited by Q3 2015+124%
TGTX TG THERAPEUTICS INCQ3 20131 of 1140.4%6.8%30Exited by Q1 2022+277%
T8S TESARO INCQ4 20131 of 833.1%3.1%4Exited by Q3 2015+108%
XNCR XENCOR INCQ4 20131 of 1023.8%3.8%13Held at last filing, Q2 2026+76%
MGNX MACROGENICS INCQ4 201310 of 1040.8%2.6%16Held at last filing, Q2 2026−83%
SCYX SCYNEXIS INCQ2 20141 of 470.9%1.1%4Exited by Q2 2015+3.5%
AKBA AKEBIA THERAPEUTICS INCQ2 20142 of 1032.2%2.2%5Exited by Q3 2017−48%
TENX TENAX THERAPEUTICS INCQ3 20143 of 561.5%1.5%10Exited by Q1 2017−50%
CHRS COHERUS BIOSCIENCES INCQ4 20141 of 1053.3%5.2%6Exited by Q2 2016+30%
AUPH AURINIA PHARMACEUTICALS INCQ4 20142 of 1001.2%1.2%3Exited by Q3 2015−17%
ASND ASCENDIS PHARMA A/SQ1 20151 of 1371.9%29.9%46Held at last filing, Q2 2026+1437%
DVAX DYNAVAX TECHNOLOGIES CORPQ1 20151 of 1166.4%6.4%4Exited by Q1 2020−75%
2655787D BLUEPRINT MEDICINES CORPQ2 20151 of 1472.5%2.7%4Exited by Q2 2016−32%
COLL COLLEGIUM PHARMACEUTICAL INCQ2 20151 of 963.0%4.9%4Exited by Q2 2016+1.7%
MCRB SERES THERAPEUTICS INCQ2 20151 of 751.1%2.5%5Exited by Q3 2021−43%
ARDX ARDELYX INCQ2 20152 of 1143.0%4.4%15Exited by Q3 2021−53%
AIMT AIMMUNE THERAPEUTICS INCQ3 20151 of 742.9%2.9%6Exited by Q1 2017−19%
NTRA NATERA INCQ3 20151 of 1671.2%1.3%6Exited by Q3 2022+227%
ACRS ACLARIS THERAPEUTICS INCQ4 20151 of 1146.8%6.8%15Held at last filing, Q2 2026−80%
WVE WAVE LIFE SCIENCES LTDQ4 20151 of 12311.2%26.3%43Held at last filing, Q2 2026−64%
ONC BEIGENE LTDQ1 20164 of 1040.6%1.1%5Exited by Q2 2017+25%
NKTR NEKTAR THERAPEUTICSQ1 20165 of 1455.6%6.5%4Exited by Q4 2023−96%
PTGX PROTAGONIST THERAPEUTICS INCQ3 20162 of 1361.6%2.1%3Exited by Q2 2017−39%
4XC1 KALVISTA PHARMACEUTICALS INCQ4 20161 of 910.6%1.8%15Exited by Q2 2022+108%
KDMN KADMON HLDGS INCQ3 20173 of 762.0%2.0%2Exited by Q1 2018+8.1%
SCPH SCPHARMACEUTICALS INCQ4 20171 of 642.9%2.9%19Exited by Q1 2023−41%
SPRO SPERO THERAPEUTICS INCQ4 20171 of 441.2%1.2%3Exited by Q3 2018+25%
IFRX INFLARX NVQ4 20172 of 575.0%5.0%8Exited by Q4 2025−94%
SG7 SAGE THERAPEUTICS INCQ4 201714 of 1326.3%6.3%5Exited by Q2 2019−3.4%
SLDB SOLID BIOSCIENCES INCQ1 20181 of 951.5%6.8%34Held at last filing, Q2 2026−91%
IOVA IOVANCE BIOTHERAPEUTICS INCQ1 20186 of 1300.9%1.4%5Exited by Q2 2019−44%
RYTM RHYTHM PHARMACEUTICALS INCQ2 20183 of 1143.1%7.3%33Held at last filing, Q2 2026+255%

Concentration and tenure

18.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
70.5%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
3
Median completed holding, quarters